Mubadala Investment Company, based in Abu Dhabi, has announced a new investment agreement with PCI Pharma Services, a global leader in the development and manufacturing of outsourced pharmaceutical solutions, particularly focusing on innovative biologic therapies. This latest funding round is part of a strategic initiative led by Bain Capital, with the current primary investor, Kohlberg, also involved. Additionally, Partners Group will maintain its support by entering as a minority investor.
This investment from Mubadala marks a continuation of its support for PCI, following an initial investment made alongside Kohlberg in 2020. Over the past five years, PCI has successfully launched more than 450 products, furthering its impressive record that spans fifty years in the pharmaceutical services sector. This ongoing commitment plays a significant role in driving innovation and enhancing patient access to advanced healthcare.
Camila Langhel, co-CEO of Mubadala’s Private Equity sector, stated, “PCI represents one of our premier investments in the healthcare domain, showcasing the achievements possible through collaboration between long-term visionary investors and strong management teams. This partnership fosters growth, creates value, and improves health outcomes for patients worldwide. We will continue to focus on similar opportunities in healthcare, especially as pharmaceutical companies increasingly seek to outsource non-core activities. This aligns with our commitment to meet clinical needs globally, reduce healthcare costs, and expand access.”
Mina Hamoudi, the head of Mubadala’s healthcare division, added, “Our decision to reinvest in PCI reaffirms our strong belief in the company’s vision, leadership, and long-term potential. At this pivotal juncture, we are pleased to welcome Bain Capital as a partner, given its substantial experience in healthcare investments and its track record in advancing pharmaceutical service companies. We look forward to a productive partnership with Bain and Kohlberg, as well as close collaboration with PCI’s exceptional management team in the next phase of the company’s accelerating growth.”
The new capital will allow PCI to pursue both organic and inorganic growth initiatives, including expanding its service offerings and geographical reach. As global demand for biologics and specialty pharmaceuticals continues to rise, the company’s future investments will focus on enhancing its current capabilities in sterile packaging for injectable medications, as well as increasing its manufacturing capacity for high-potency drugs and specialized manufacturing techniques. This strategic investment will also enable PCI to continue its significant investments in the United States, strengthening the crucial infrastructure for drug manufacturing and supply chains in the country.